http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Jong Hyung Kim ),( Sung Jo Bang ),( Jung Woo Shin ),( Hyung Wook Joo ),( Bo Ryung Park ),( Chang Jae Kim ),( Byung Gyu Kim ),( Seok Won Jung ),( In Du Jeong ),( Neung Hwa Park ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background: In patients with an insufficient virologic suppression, i.e., a detectable hepatitis B virus (HBV) DNA during antiviral treatment, a drug change or addition of a more efficacious drug is recommended. However, the clinical courses of patients with insufficient virologic suppression in chronic hepatitis B (CHB) patients with entecavir (ETV) therapy are unclear. Methods: The retrospective cohort study investigated the long-term clinical outcomes of ETV treatment of more than 3 years in 266 nucleos(t)ide-naive CHB patients, particularly those with insufficient virologic suppression. Results: All of the patients were genotype C2. Virologic response (VR) was achieved in 244 patients (91.7%) at 3 years of treatment. Virologic breakthrough was observed in four (1.5%) patients. Of these four patients, only one (0.4%) had genotypic resistance to ETV. The insufficient virologic suppression was defined as primary non-response (PNR), inadequate (IVR), or partial VR (PVR) according to residual HBV DNA levels at 12, 24, and 48 weeks of treatment, respectively. PNR, IVR, and PVR were evident in 5 (1.9%), 20 (7.5%), and 39 (14.7%) patients, respectively. During continuous prolonged ETV therapy, VR of patients with PNR, IVR, and PVR was achieved in five (100%), 10 (50%), and 22 (56.4%) patients, respectively. Conclusions: The vast majority of CHB patients achieved VR through prolonged ETV therapy, with only 0.4% chance of viral resistance up to 3 years of treatment. Furthmore, most patients with the insufficient virologic suppression such as PVR, as well as PNR and IVR could achieve VR without adjustment of antiviral therapy.
( Jong Hyung Kim ),( Sung Jo Bang ),( Jung Woo Shin ),( Hyung Wook Joo ),( Bo Ryung Park ),( Chang Jae Kim ),( Byung Gyu Kim ),( Seok Won Jung ),( In Du Jeong ),( Neung Hwa Park ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: In patients with an insufficient virologic suppression, i.e., a detectable hepatitis B virus (HBV) DNA during antiviral treatment, a drug change or addition of a more efficacious drug is recommended. However, the clinical courses of patients with insufficient virologic suppression in chronic hepatitis B (CHB) patients with entecavir (ETV) therapy are unclear. Methods: The retrospective cohort study investigated the long-term clinical outcomes of ETV treatment of more than 3 years in 266 nucleos(t)ide-naive CHB patients, particularly those with insufficient virologic suppression. Results: All of the patients were genotype C2. Virologic response (VR) was achieved in 244 patients (91.7%) at 3 years of treatment. Virologic breakthrough was observed in four (1.5%) patients. Of these four patients, only one (0.4%) had genotypic resistance to ETV. The insufficient virologic suppression was defined as primary non-response (PNR), inadequate (IVR), or partial VR (PVR) according to residual HBV DNA levels at 12, 24, and 48 weeks of treatment, respectively. PNR, IVR, and PVR were evident in 5 (1.9%), 20 (7.5%), and 39 (14.7%) patients, respectively. During continuous prolonged ETV therapy, VR of patients with PNR, IVR, and PVR was achieved in five (100%), 10 (50%), and 22 (56.4%) patients, respectively. Conclusions: The vast majority of CHB patients achieved VR through prolonged ETV therapy, with only 0.4% chance of viral resistance up to 3 years of treatment. Furthmore, most patients with the insufficient virologic suppression such as PVR, as well as PNR and IVR could achieve VR without adjustment of antiviral therapy.